



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

## ROME, FEBRUARY 23<sup>rd</sup>-26<sup>th</sup>, 2011

### 13<sup>th</sup> AISF PRE-MEETING COURSE

#### “Difficult Clinical Issues in Hepatology”

Aula Magna, Università di Roma “Sapienza” - P.le A. Moro, 5

Course Directors: F. Piscaglia, Bologna and P. Toniutto, Udine

### 44<sup>th</sup> AISF ANNUAL MEETING

Aula Magna, Università di Roma “Sapienza” - P.le A. Moro, 5

### 4<sup>th</sup> AISF POST-MEETING COURSE

#### “Unmet Clinical Needs in Hepatology”

Auditorium, Centro Congressi Frentani - Via dei Frentani, 4

Course Directors: M. Fraquelli, Milan and G. Missale, Parma

## SCIENTIFIC PROGRAMME

### Wednesday, February 23<sup>rd</sup>

09.30-10.45 **Registration and Entry questionnaire**

10.45-11.00 **Course Presentation**

F. Piscaglia & P. Toniutto

#### Session I

##### Portal hypertension

Chairpersons: P. Caraceni, Bologna  
G.L. Rapaccini, Rome

#### Session III

##### Liver failure

Chairpersons: P. Burra, Padua  
A. Gasbarrini, Rome

11.00-11.20 Management of refractory  
gastrointestinal bleeding in cirrhosis  
G. D'Amico, Palermo

15.30-15.50 Indications for artificial liver support  
systems  
P. Angeli, Padua

11.20-11.40 Management of refractory ascites  
F. Salerno, Milan

15.50-16.10 Criteria to refer patient with complicated  
liver cirrhosis and fulminant liver failure  
to intensive care unit  
A. Ottobrelli, Turin

11.40-12.00 Management of chronic hepatic  
encephalopathy  
P. Amodio, Padua

16.10-16.30 *Discussion*

12.00-12.20 Diagnosis and management of pre-  
hepatic portal hypertension  
J. De Ville De Goyet, Rome

16.30-16.50 **Break**

#### Session IV

##### Surgery and oncology in hepatology

Chairpersons: B. Daniele, Benevento  
M. Rossi, Rome

12.20-13.00 *Discussion*

13.00-14.00 **Lunch**

#### Session II

##### Viral hepatitis

Chairpersons: S. Bruno, Milan  
A. Picciotto, Genoa

16.50-17.10 Evaluation of surgical risk in patients with  
liver diseases  
S. Fagioli, Bergamo

14.00-14.20 Management of severe side effects due  
to antiviral drugs in responder patients  
G.B. Gaeta, Naples

17.10-17.30 Management of rare liver tumours  
G.L. Grazi, Rome

14.20-14.40 Clinical management of viral hepatitis in  
dialysis  
A. Mangia, S. Giovanni Rotondo

17.30-17.50 Management of side effects of anti  
angiogenic inhibitors in treating  
hepatocellular carcinoma  
M. Di Maio, Naples

14.40-15.10 Clinical management of viral hepatitis  
during pregnancy and breast feeding  
G. Indolfi, Florence

17.50-18.10 *Discussion*

15.10-15.30 *Discussion*

18.10-18.40 **General Assembly I**



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

## 44<sup>th</sup> Annual Meeting of the Italian Association for the Study of the Liver - AISF

Aula Magna, Università di Roma "Sapienza" - P.le A. Moro, 5  
Rome, February 24<sup>th</sup>-25<sup>th</sup>, 2011

### Thursday, February 24<sup>th</sup>

#### 08.30-10.00 Oral Communications

Chairpersons: M. Levvero, Rome  
M. Pirisi, Novara

#### Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma

M. Iavarone, G. Cabibbo, A. Sangiovanni, C. Cammà, A. Borghi, C. Zavaglia, A. Grieco, A. Granito, A. Airoidi, M. Biolato, V. Di Marco, F. Piscaglia, G.B. Pinzello, S. Racco, L. Bolondi, A. Craxi and M. Colombo - Milan, Palermo, Bologna, Rome

#### Genetic variation in IL28B polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated with interferon alfa

P. Lampertico, M. Viganò, C. Cheroni, F. Facchetti, V. Valveri, R. Soffredini, S. Abrignani, R. De Francesco, M. Colombo - Milan

#### MicroRNA-519d is up-regulated in hepatocellular carcinoma and sensitizes HCC cells to Doxorubicin treatment by targeting CDKN1A/p21

F. Fornari, L. Gramantieri, M. Milazzo, G. Pallocca, S. Francia, M. Cescon, M. Negrini, L. Bolondi - Bologna, Ferrara

#### Over-expression of SERPINB3 in hepatoblastoma: a possible insight into the genesis of this tumor?

C. Turato, M.A. Buendia, M. Fabre, M.J. Redon, S. Branchereau, S. Quarta, M.G. Ruvoletto, G. Perilongo, M.A. Grotzer, A. Gatta, P. Pontisso Padua, Paris, Villejuif (France), Bicêtre (France), Zurich (Switzerland)

#### Cytoskeletal rearrangement by the mitogen-activated protein kinase ERK5 interferes with the motile and invasive phenotype of hepatocellular carcinoma cells

G. Di Maira, E. Rovida, N. Navari, K. Rombouts, S. Cannito, P. Dello Sbarba, M. Parola, F. Marra - Firenze, Turin

#### Vitamin D Serum Level and IL28B rs12979860 polymorphism are related to rapid virological response to IFN-based therapy in genotype 1 chronic hepatitis C

S. Petta, S. Grimaudo, D. Ferraro, C. Cammà, D. Cabibi, A. Di Cristina, V. Di Marco, A. Mazzola, C. Scazzone, R. Di Stefano, A. Craxi - Palermo

#### 10.00-10.30 State-of-the-art Lecture

Introduced by: R. Bruno, Pavia

#### Gene expression and hepatitis C virus infection

T. Asselah, Clichy, France

#### 10.30-11.00

Break and Posters view

Tutors: M. Marzioni, Ancona  
S. Petta, Palermo

#### 11.00-12.00

General Assembly II

#### 12.00-13.30

Oral Communications

Chairpersons: M. Mondelli, Pavia  
G. Raimondo, Messina

#### A SVR to post-LT antiviral treatment improves long-term survival in patients with genotype 1 HCV recurrence: an "AISF RECOLT-C" group study

F.R. Ponziani, A. Milani, A. Gasbarrini, R. Viganò, R.M. Iemmolo, M.F. Donato, M. Rendina, P. Toniutto, L. Pasulo, M. Cescon, E. De Martin, L. Miglioresi, V. Giannelli, D. Di Paolo, S. Agnes, S. Faggiuoli, M. Pompili, AISF RECOLT-C group and Fondazione Ricerca in Medicina - Rome, Milan, Modena, Bari, Udine, Bergamo, Bologna, Padua

#### Analysis and characterization of HBV DNA integration in patients with occult HBV infection and hepatocellular carcinoma

C. Saitta, T. Pollicino, G. Raffa, A. Bertuccio, A. Barbera, A. Ciancio, A. Smedile, G. Navarra, G. Raimondo - Messina, Turin

#### The presence of hepatitis C virus deletion mutants in chronic hepatitis C patients and their role during PEG-IFN/ribavirin therapy

L. Donnici, C. Cheroni, A. Aghemo, M.G. Rumi, V. Valveri, R. Soffredini, G.M. Prati, M. Colombo, S. Abrignani, R. De Francesco - Milan



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

**Effect of low molecular weight heparin (LMWH) on thrombin generation in cirrhotic patients**

K.I. Rodriguez, V. Rossetto, C. Radu, P. Dabrilli, S. Gavasso, P. Burra, P. Simioni, M. Senzolo - *Padua*

**STAT1 and STAT2 transcription factors expression is upregulated in HBV replicating cells by distinct mechanisms**

L. Belloni, F. Guerrieri, C. Scisciani, T. Pollicino, G. Raimondo, M. Levrero *Rome, Messina*

**Pegylated interferon-alpha potently augments NK cell antiviral effector function in chronic hepatitis B**

L. Micco, D. Peppà, E. Loggi, A. Schurich, C. Cursaro, A. Martello Panno, F. Bihl, M. Bernardi, P. Andreone, M.K. Maini - *Bologna, Bellinzona (Switzerland)*

13.30-14.45 *Lunch and Posters view*  
*Tutors: A. Aghemo, Milan*  
*L. Fabris, Padua*

14.45-15.15 **Young Investigator Lecture**  
Clinical usefulness of platelet count in management of liver disease  
E.G. Giannini, *Genoa*  
*Chairperson: A. Craxì, Palermo*

15.15-15.45 **2009 AISF Fellowships Report**  
*Introduced by: C. Ferrari, Parma*

15.15-15.30 Mitochondrial apotopes: the key for biliary specificity in primary biliary cirrhosis  
A. Lleo De Nalda, *Milan*

15.30-15.45 NS3 genetic variants resistant to protease inhibitors in HCV-1b isolates from liver tissues of naïve patients with chronic hepatitis C  
S. Maimone, *Messina*

15.45-16.15 **State-of-the-Art Lecture**  
*Introduced by: A. Gatta, Padua*  
**Update on Baveno Consensus Conference**  
R. de Franchis, *Milan*

16.15-16.45 Break and poster view  
*Tutors: M. Marziani, Ancona*  
*S. Petta, Palermo*

16.45-17.00 **Report of Italian Liver Patients Associations**  
EpaC - I. Gardini, *Milan*  
Liver Pool - S. Ricca Rosellini, *Forlì*  
*Chairperson: C. Puoti, Marino*

17.00-18.30 **Oral Communications**  
*Chairpersons: F. Bonino, Pisa*  
*D. Conte, Milan*

**ADVANCE Study: final results of the phase III trial with telaprevir in combination with PEG-IFN and RBV in genotype treatment-naïve 1 HCV**

M. Rizzetto, P. Andreone, M. Colombo, A. Scuteri, A. Ciancio, A. Smedile, N. Adda, I.M. Jacobson - *Turin, Bologna, Milan, Cambridge (MA, USA), New York (NY, USA)*

**miR-224 is a direct target of HBx and modulates HBV replication**

C. Scisciani, L. Belloni, F. Guerrieri, M. Levrero, N. Pediconi - *Rome*

**Accelerated chemically-induced liver fibrosis in hemojuvelin knockout mice mediated by early induction of profibrogenic cytokines**

G. Sebastiani, K. Gkouvatsos, M. Guido, C. Maffettone, K. Pantopoulos - *Montreal (Quebec, Canada), Padua*

**Interaction between the PNPLA3 I148M mutation and body weight in determining steatosis and the progression to cirrhosis in hereditary hemochromatosis**

P. Maggioni, A. Piperno, E. Galmozzi, S. Pelucchi, R. Rametta, R. Mariani, P. Dongiovanni, A.L. Fracanzani, S. Fargion, L. Valenti - *Milan*

**HCV burden in Europe: impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach**

T. Stroffolini, S. Deuffic-Burban, P. Deltenre, M. Buti, J. Parkes, N. Mühlberger, U. Siebert, C. Moreno, A. Hatzakis, W. Rosenberg, S. Zeuzem, P. Mathurin - *Rome, Lille (France), Haine-Saint-Paul (Belgium), Barcelona (Spain), Southampton (UK), Innsbruck (Austria), Boston (MA, USA), Brussels (Belgium), Athens (Greece), London (UK), Frankfurt (Germany)*

**Liver stiffness measurement as non-invasive tool for the assessment of portal hypertension in cirrhotic patients**

F. De Filippi, C. Facciotto, A. Camera, F. Gattoni, S. Rossi, A. Chiesa, P. Maisonneuve, S. Raimondi and S. Bruno - *Milan*



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

## Friday, February 25<sup>th</sup>

08.30-10.00

### Oral Communications

Chairpersons: N. Caporaso, *Naples*  
M. Puoti, *Milan*

#### **Modelling HCV kinetics by IL28B genotype is a new accurate tool for individual treatment management**

P. Colombatto, C. Giannini, F. Oliveri, P. Ciccorossi, B. Coco, B. Cherubini, L. Civitano, D. Cavallone, A. Stabile, V. Romagnoli, C. Rastelli, F. Moriconi, A.L. Zignego, F. Bonino and M.R. Brunetto - *Pisa, Florence*

#### **IL28B SNPs (rs8099917 and rs8099860) are associated with spontaneous HCV clearance, progression of fibrosis and response to IFN in Thalassemia Major (TM) patients**

V. Di Marco, F. Bronte, V. Calvaruso, M. Capra, A. Maggio, R. Malizia, M. Rizzo, C. Gerardi, S. Grimaudo, M. Levrero, A. Craxi - *Palermo, Gruppo Cooperativo Siciliano per lo Studio della Talassemia, Rome*

#### **Study of HDV interference on HBV replication in human hepatoma cell lines**

G. Raffa, G. Raimondo and T. Pollicino  
*Messina*

#### **Vitamin A deficiency negatively affects the response to antiviral treatment in patients with chronic hepatitis C**

D. Bitetto, N. Bortolotti, S. Vescovo, G. Fattovich, E. Ceriani, M. Pasino, C. Cristofori, A. Cussigh, C. Fabris, E. Fornasiere, S. Cmet, E. Fontanini, E. Falleti, M. Pirisi, P. Toniutto - *Udine, Verona, Novara*

#### **PNPLA3 sequence variant (RS738409) confers susceptibility to HCV related cirrhosis in Europeans**

S. Ginanni Corradini, M.A. Burza, M.R. Thursz, P. Toniutto, C. Pirazzi, C. Maglio, E. Falleti, A. Molinaro, M. Siciliano, M. Mordenti, L. Parlati, C. Fabris, F. Ferri, A. De Santis, M. Rossi, P. Bianco and S. Romeo - *Rome, London (UK), Udine, Gothenburg (Sweden)*

#### **The best matching for HCV genotype 1 liver transplant recipients is predicted by HCV1-STAR. A Study from "AISF RECOLT-C" database**

F.R. Ponziani, A. Milani, A. Gasbarrini, R. Viganò, R.M. Iemmolo, M.F. Donato, M. Rendina, P. Toniutto, L. Pasulo, M.C. Morelli, E. De Martin, L. Miglioresi, V. Giannelli, D. Di Paolo, S. Agnes, S. Faggioli, M. Pompili, AISF RECOLT-C group and Fondazione Ricerca in Medicina - *Rome, Milan, Modena, Bari, Udine, Bergamo, Bologna, Padua*

10.00-10.30

#### **Break and Poster view**

Tutors: A. Aghemo, *Milan*  
L. Fabris, *Padua*

10.30-10.45

#### **Presentation of the AISF prize for the best Italian paper in 2009**

Chairperson: C. Cammà, *Palermo*

#### **Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C** **Hepatology 2009;50(3):697-706**

E. Vanni, M.L. Abate, E. Gentilcore, I. Hickman, R. Gambino, M. Cassader, A. Smedile, E. Ferrannini, M. Rizzetto, G. Marchesini, A. Gastaldelli, E. Bugianesi - *Turin*

10.45-11.00

#### **Feedback on the use of AISF electronic clinical record**

G. Svegliati Baroni, *Ancona*

11.00-11.15

#### **Presentation of the AISF-ISS research project**

R. Bruno, *Pavia* - S. Vella, *Rome*

11.15-12.05

#### **State-of-the-Art Lecture**

Introduced by: M. Colombo, *Milan*

#### **Bibliometrics and Scientific Resource on the WEB**

V. Pistotti, *Milan*

12.05-13.05

#### **Oral Communications**

Chairpersons: G. Taliani, *Rome*  
M. Zoli, *Bologna*

#### **Survival and prognosis of hepatorenal syndrome type-1 in the era of vasoconstrictor therapy**

M. Cazzaniga, C. Dibenedetto, V. Monti, S. Accordino, G. Gobbo, F. Salerno - *Milan*

#### **Carvedilol compared to propranolol for portal hypertension in cirrhosis**

E. Sinagra, M. D'Amico, G. Perricone, G. D'Amico - *Palermo*



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

**Diagnostic accuracy of different patterns of contrast enhanced ultrasound in characterization of new nodules in liver cirrhosis with and without history of previous hepatocellular carcinoma**

S. Leoni, F. Piscaglia, A. Granito, V. Salvatore, A. Cappelli, V. Lucidi, R. Golfieri, L. Bolondi - *Bologna*

**Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma: a randomized controlled trial**

G.G. Di Costanzo, R. Tortora, G. D'Adamo, A. Galeota Lanza, N. Carannante, F. Lampasi, M. De Luca, M.T. Tartaglione, S. Mattera, C.M. Pacella - *Naples*

13.05-14.05 *Lunch and Poster view*

Tutors: M. Marzioni, *Ancona*  
S. Petta, *Palermo*

14.05-15.00 **General Assembly III**

15.00-15.15 **Presentation of the AISF distinguished service award to Prof. Giovanni Gasbarrini**

*Introduced by:* R. Bruno, *Pavia*  
*Presenter:* M. Bernardi, *Bologna*

15.15-17.00 **Oral Communications**

*Chairpersons:* A. Benedetti, *Ancona*  
M. Rizzetto, *Turin*

**The allocation policy of liver grafts from HBcAb positive donors needs to be improved: evidence from the Liver-Match cohort study**

T. Marianelli, U. Cillo, S. Fagioli, D. Prati, M. Strazzabosco, C. Gavrila, A. Nardi and M. Angelico, *on behalf of Liver Match investigators, AISF and CNT, and Italian Liver Transplant Centers*

**Adrenal dysfunction in nonseptic cirrhotic patients with ascites: impact on survival**

A. Risso, C. Alessandria, C. Elia, L. Mezzabotta, A. Andrealli, M. Spandre, A. Morgando, A. Marzano, M. Rizzetto - *Turin*

**Recipient IL-28B rs12979860 C>T polymorphism predicts acute cellular rejection in liver transplanted patients**

D. Bitetto, A. Cussigh, E. Fornasiere, S. Cmet, E. Fumolo, S. Bignulin, E. Fontanini, E. Bignulin, E. Falletti, C. Fabris, M. Pirisi, P. Toniutto - *Udine, Novara*

**Healthy ranges for serum alanine aminotransferase concentration. It's time for a new update?**

D. Prati, F. Cappiello, A. Berzuini, M. Spreafico, I. Guarnori, L. Raffaele, C. Bonato, P.G. Duca, A. Colli - *Lecco, Milan*

**Evaluation of intestinal barrier function and histologic aspects "in vivo" and its normalization after  $\beta$ -blocker treatment in patients with cirrhosis and portal hypertension**

E. Nadal, A. Buda, D. Pizzuti, L. Nai, P. Burra, M. Senzolo - *Padua*

**HCV replication in patients with onco-haematological diseases**

N. Coppola, M. Pisaturo, S. Guastafierro, G. Tonziello, A. Sica, V. Iodice, C. Sagnelli, M.G. Ferrara, E. Sagnelli - *Naples, Caserta*

**Hypothalamus-pituitary dysfunction accounts for adrenal insufficiency in cirrhosis**

G. Fede, M. Thomas, D. Georgiadis, P. Vasianopoulou, M. Yago-Baenas, L. Spadaro, T. Tomaselli, G. Privitera, P.M. Bouloux, F. Purrello, A.K. Burroughs - *London (UK), Catania*

17.00-17.15 **Young Investigators Awards**

*Presenters for the 2 best oral communications*

*Basic:* P. Pontisso, *Padua*  
*Clinical:* M.G. Rumi, *Milan*

*Presenters for the 2 best posters*

*Basic:* L. Fabris, *Padua*  
M. Marzioni, *Ancona*

*Clinical:* A. Aghemo, *Milan*  
S. Petta, *Palermo*





# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

## POSTER SESSION Thursday, February 24<sup>th</sup>

- N° 1 Preliminary clinical results of thermal ablation of primary and metastatic tumor lesions with a new percutaneous microwaves device**  
G. Poggi, M. Mazzucco, B. Montagna, B. Tagliaferri, F. Sottotetti, G. Bernardo - *Pavia*
- N° 2 The evolving clinical scenario of hepatocellular carcinoma over the last 20 years in Italy**  
V. Santi, D. Buccione, G. Fatti, A. Di Micoli, F. Farinati, P. Del Poggio, G. Rapaccini, M.A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E.G. Giannini, E. Caturelli, M. Chiaramonte, M. Bernardi, F. Trevisani, for the ITA.LI.CA Group *Bologna, other ITA.LI.CA. centres*
- N° 3 A review of late acute rejection in the era of tacrolimus therapy; a study of its natural history, incidence, risk factors and graft survival**  
P. Thurairajah, M. Carbone, H. Bridgestock, P. Thomas, S. Hebbbar, B. Gunson, T. Shah, J. Neuberger - *Birmingham (UK)*
- N° 4 A 20-years survey by ITA.LI.CA on hepatocellular carcinoma (HCC) in HCV-related cirrhosis**  
N. Cazzagon, F. Trevisani, A. Giacomini, A. Sergio, V. Vanin, C. Pozzan, P. Del Poggio, G. Rapaccini, M.A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E.G. Giannini, E. Caturelli, M. Chiaramonte, F. Farinati - *Padua, ITA.LI.CA study group*
- N° 5 Oncostatin M, overexpressed in hepatocellular carcinoma, up-regulates SERPIN-B3 expression in hepatic cancer cells**  
S. Cannito, C. Turato, C. Paternostro, S. Quarta, E. Novo, C. Busletta, D. Povero, E. David, S. Colombatto, P. Pontisso, M. Parola - *Turin, Padua*
- N° 6 Oncostatin M stimulates chemotaxis of human hepatic profibrogenic cells**  
C. Busletta, E. Novo, C. Paternostro, K. Mareschi, S. Cannito, D. Povero, E. David, S. Colombatto, F. Marra, F. Fagioli, M. Pinzani, M. Parola *Turin, Florence*
- N° 7 Intraocular complications during antiviral therapy for hepatitis C are common and more frequent in patients with hypertension and/or diabetes: results of a prospective, longitudinal study**  
G. Sebastiani, S. Vujosevich, E. Midena, A. Saggiaro, D. Tempesta - *Venice, Padua*
- N° 8 Epidermal growth factor rs4444903 G/G genotype in chronic hepatitis C: relationship with a worse disease and a more rapid fibrotic evolution**  
D. Bitetto, S. Cmet, E. Fornasiere, A. Cussigh, E. Fumolo, S. Bignulin, E. Fontanini, E. Bignulin, E. Falletti, C. Fabris, M. Pirisi, P. Toniutto - *Udine, Novara*
- N° 9 Interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases**  
E. Fornasiere, S. Cmet, D. Bitetto, A. Cussigh, E. Fumolo, S. Bignulin, E. Fontanini, C. Colletta, C. Vandelli, E. Ceriani, C. Smirne, E. Bignulin, E. Falletti, C. Fabris, P. Toniutto, M. Pirisi - *Udine, Omega, Modena, Novara*
- N° 10 Effect of prevalence of fibrosis stages on the performance of non-invasive fibrosis biomarkers in chronic liver diseases (CLDs): results of a large-scale, international study**  
G. Sebastiani, P. Halfon, L. Castera, S. Pol, D.L. Thomas, A. Mangia, V. Di Marco, M. Pirisi, M. Voiculescu, M. Bourliere, A. Alberti - *Padua, Marseille (France), Bordeaux (France), Paris (France), Baltimore (MD, USA), San Giovanni Rotondo, Palermo, Novara, Bucharest (Romania)*
- N° 11 Adiponectin in nonalcoholic fatty liver disease: correlation with liver damage and PNPLA3 genotype**  
R. Rametta, E. Canavesi, M. Ruscica, A.L. Fracanzani, P. Dongiovanni, E. Galmozzi, P. Magni, S. Fargion, L. Valenti - *Milan*
- N° 12 Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: a possible marker of metabolic syndrome and early vascular damage**  
R. Lombardi, T. Tonella, F. Massari, L. Valenti, C. Bertelli, L. Burdick, D. Bignamini, E. Fatta, S. Fargion, A.L. Fracanzani - *Milan*
- N° 13 Protective effect of coffee on oxidative DNA damage in patients with HCV-chronic hepatitis**  
M. Picciocchi, R. Cardin, D. Martinez, L. Scribano, A. Floreani, M. Petracco, F. Farinati - *Padua, ISIC (Switzerland)*
- N° 14 The outcome of pregnancy in patients with primary sclerosing cholangitis**  
S. Antoniazzi, M.T. Gervasi, L. Costa, N. Cazzagon, A. Floreani - *Padua*



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- N° 15 PNPLA3 rs734809 C/G polymorphism in liver cirrhosis: relationship with the etiology of liver disease and HCC occurrence**  
D. Bitetto, E. Fornasiere, S. Cmet, A. Cussigh, E. Fumolo, S. Bignulin, E. Fontanini, E. Bignulin, E. Falletti, C. Fabris, M. Pirisi, P. Toniutto - *Udine, Novara*
- N° 16 Follow up of esophageal varices at 3 vs 6 months after eradication by endoscopic banding in cirrhotic patients. A prospective randomized trial**  
G. Ferruzzi, W. Debernardi Venon, C. Elia, A. Musso, M. Bruno, G. Saracco, M. Rizzetto  
*Turin*
- N° 17 Impact of Gadoxetic acid (Gd-EOB-DTPA)-enhanced MR on the non-invasive diagnosis of small hepatocellular carcinoma**  
M. Galassi, A. Granito, F. Piscaglia, A. Borghi, V. Lucidi, R. Golfieri, L. Bolondi - *Bologna*
- N° 18 Liver follicular helper T-cells in chronic hepatitis C**  
C. Tripodo, S. Petta, D. Ferraro, C. Guarnotta, D. Cabibi, M. Colombo, S. Grimaudo, R. Pipitone, A. Craxì - *Palermo, Milan*
- N° 19 Higher thyroid-stimulating hormone serum level is related to severe fibrosis in genotype 1 chronic hepatitis C patients with normal thyroid function**  
S. Petta, A. Mazzola, M. Donatelli, G.C. Morreale, C. Cammà, D. Cabibi, V. Di Marco, A. Craxì - *Palermo*
- N° 20 Visceral adiposity index, expression of adipose dysfunction, is associated with significant fibrosis in patients with non-alcoholic fatty liver disease**  
S. Petta, M. Amato, G. Licata, M. Barcellona, C. Cammà, D. Cabibi, V. Di Marco, C. Giordano, D. Sinagra, A. Galluzzo, A. Craxì  
*Palermo*
- N° 21 Portal vein thrombosis affects prognosis of cirrhotic patients with previous variceal haemorrhage**  
L. Amitrano, M.A. Guardascione, A. Menchise, R. Martino, M. Scaglione, A. Balzano - *Naples*
- N° 22 Effect of dietary intervention and weight loss on circulating and hepatic expression of fibroblast growth factor-21 in non alcoholic steatohepatitis**  
D. Donnini, D. Cappello, A. Carnelutti, V. Bonasia, C. Pagano, R. Vettor, F. Favaretto, S. Leandri, L. Sechi, G. Soardo - *Udine, Padua*
- N° 23 Poor adherence to pegylated interferon and ribavirin is a major concern in the treatment of hepatitis C after liver transplantation: evidence from the AISF recolt-C study group**  
D. Di Paolo, F.R. Ponziani, S. Fagioli, R. Viganò, R.M. Iemmolo, M.F. Donato, M. Rendina, M.C. Morelli, P. Toniutto, L. Miglioresi, E. De Martin, M. Merli, G. Tisone, M. Angelico  
*Italian Association for the Study of the Liver (AISF) Liver Transplantation-HCV Group*
- N° 24 Donor-related characteristics as predictors of sustained virologic response to antiviral therapy in recurrent hepatitis C after liver transplantation**  
R.M. Iemmolo, M. Marino, R. Montalti, F. Ponziani, R. Viganò, E. De Martin, M.F. Donato, M. Rendina, M. Cescon, D. Di Paolo, E. Fornasiere, L. Miglioresi, V. Giannelli, S. Fagioli, G.E. Gerunda, for the AISF-RECOLT-C group - *Modena, Rome, Milan, Padua, Bari, Bologna, Udine, Bergamo*
- N° 25 Impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in HCV genotype 1 treatment-naive: results from C208 sub-analysis**  
G. Carosi, M. Colombo, A. Spinetti, S. Zaltron, L. Serfaty, P. Marcellin, I. Lonjon-Domanec, R. De Masi, M. Beumont - *Brescia, Milan, Paris (France), Clichy (France), Issy les Moulineaux (France), Titusville (NJ, USA), Beerse (Belgium)*
- N° 26 Long-term FU of patients with CHC treated with telaprevir in combination with PEG-IFN alfa-2a and RBV:interim analysis of the extend study**  
A. Alberti, S. Zeuzem, M.S. Sulkowski, F. Zoulim, K.E. Sherman, L.J. Wei, B. van Baelen, J. Sullivan, T.L. Kieffer, S. De Meyer, G. Picchio, F. Tomaka, C. Graham and J.G. McHutchison - *Padua, Frankfurt am Main (Germany), Baltimore (MD, USA), Lyon (France), Cincinnati (OH, USA), Boston (MA, USA), Mechelen (Belgium), Cambridge (MA, USA), Titusville (NJ, USA), Durham (NC, USA)*
- N° 27 The antifibrotic effect of sorafenib is due to decreased HSCs activation mediated by angiogenesis blockage**  
S. De Minicis, L. Agostinelli, C. Rychlicki, S. Saccomanno, L. Trozzi, I. Pierantonelli, A. Benedetti, G. Svegliati-Baroni - *Ancona*
- N° 28 A metabolic switch in rat liver: correlation between temperature and hypoxia-inducible factor-1-alpha expression**  
A. Ferrigno, A. Bianchi, P. Richelmi, E. Gringeri, D. Neri, G. Ramadori, U. Cillo, M. Vairetti  
*Pavia, Padua, Göttingen (Germany)*



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- N° 29 Early NK cell activation predicts successful treatment outcome in chronic HCV infection**  
B. Oliviero, D. Mele, E. Degaspero, E. Cremonesi, S. Varchetta, A. Aghemo, M.G. Rumi, C. Tinelli, M. Colombo, M.U. Mondelli - *Pavia, Milan*
- N° 30 Cognitive profiles in patients with cirrhosis and long-term liver transplant recipients**  
M. Giovagnoli, B. Lenzi, S. Schiff, P. Amodio, M. Zoli, S. Montagnese, G. Bianchi - *Bologna, Padua*
- N° 31 Nonalcoholic fatty liver disease and aging. Clinical course and cardiovascular risk**  
G. Corvalli, G. Bianchi, G. Girotti, B. Lenzi, M. Giovagnoli, A. Cenni, A. Muscari, D. Magalotti, M. Zoli, and the Pianoro Study Group - *Bologna*
- N° 32 Positive cardiac inotropic effect of albumin infusion in rats with cirrhosis and ascites: molecular mechanisms**  
A. Bortoluzzi, A. Sticca, G. Segato, G. Ceolotto, S. Bova, A. Gatta and P. Angeli - *Padua*
- N° 33 Liver steatosis in old subjects could be a predictor of possible cardiac abnormalities**  
P. Zappoli, A. Cenni, G. Bianchi, V. Rossi, D. Magalotti, A. Muscari, M. Zoli, the Pianoro Study Group - *Bologna*
- N° 34 Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions**  
G. Fattovich, L. Covolo, S. Bibert, G. Askarieh, M. Lagging, S. Clément, G. Malerba, M. Pasino, M. Guido, M. Puoti, G.B. Gaeta, T. Santantonio, G. Raimondo, R. Bruno, P.-Y. Bochud, F. Donato, F. Negro on behalf of the ITAHEC Study Group - *Verona, Geneva (Switzerland)*
- N° 35 In CHC patients aged  $\geq 50$  years ribavirin-induced anemia depends on renal function**  
G. Borroni, M. Andreoletti, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, M.G.L. Pich, A. Prada, G. Spinzi, N.M. Terreni *Milan, Abbiategrasso, Lecco, Rho, Legnano, Rozzano, Varese, Como*
- N° 36 Fibrosis progression in patients with chronic hepatitis C is not influenced by IL28B polymorphisms**  
A. Aghemo, F. Marabita, S. De Nicola, M.G. Rumi, C. Cheroni, R. Scavelli, M. Crimi, R. Soffredini, S. Abrignani, R. De Francesco and M. Colombo - *Milan*
- N° 37 Distribution of the IL28B rs12979860 polymorphism and its influence on sustained virological response rates in the MIST trial**  
A. Aghemo, M.G. Rumi, C. Cheroni, G.M. Prati, L. Donnici, V. Zanoni, R. Soffredini, S. Abrignani, R. D'Ambrosio, R. De Francesco and M. Colombo *Milan*
- N° 38 PEG-IFN for hepatitis C in clinical practice: results of the retrospective phase of the AIFA study**  
F. Rosina, M.E. Tosti, E. Borghesio, A. Mele, S. Monastra, R. Bruno, N. Caporaso, G. Carosi, E. Sagnelli, M. Rizzetto (Study Coordinator) and the AIFA Study Group - *Turin, Rome, Naples, Pavia, Brescia, Caserta*
- N° 39 Biological downstaging of intermediate hepatocellular carcinoma in patients treated with sorafenib**  
A. Vitale, R. Ramirez Morales, U. Cillo - *Padua*
- N° 40 Rebleeding does not affect prognosis of cirrhotic patients with advanced hepatocellular carcinoma**  
L. Amitrano, G.G. Di Costanzo, M.A. Guardascione, A. Menchise, R. Martino, A. Balzano - *Naples*
- N° 41 Sorafenib for the treatment of advanced hepatocellular carcinoma: effectiveness and impact of adverse effects in daily clinical practice**  
R. Tortora, A. Galeota Lanza, F. Lampasi, M. De Luca, R. Pacilio, M.T. Tartaglione, S. Mattered, G.G. Di Costanzo - *Naples*
- N° 42 A sustained virological response to interferon prevents insulin resistance in chronic hepatitis C patients**  
G.M. Prati, A. Aghemo, M.G. Rumi, R. Soffredini, R. D'Ambrosio, S. De Nicola, E. Degaspero, L. Olgiati and M. Colombo - *Milan*
- N° 43 Treatment of the "uncommon" HCV genotype 4 infection recurrence after liver transplantation. Data from AISF RECOLT-C group**  
F.R. Ponziani, A. Milani, A. Gasbarrini, R. Viganò, M. Marino, M.F. Donato, M. Rendina, P. Toniutto, M.C. Morelli, E. De Martin, L. Miglioresi, V. Giannelli, D. Di Paolo, S. Agnes, S. Fagioli, M. Pompili, AISF RECOLT-C group and Fondazione Ricerca in Medicina - *Rome, Milan, Modena, Bari, Udine, Bologna, Padua, Bergamo*





# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

**N° 44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: results from the AISF RECOLT-C study group**

E. De Martin, M. Senzolo, F.R. Ponziani, D. Di Paolo, R. Viganò, M. Marino, M.F. Donato, M. Rendina, M.C. Morelli, E. Fornasiero, L. Miglioresi, V. Giannelli, S. Fagioli, P. Burra Padua, Rome, Milan, Modena, Bari, Bologna, Udine, Bergamo

**N° 45 Improved diagnostic accuracy for HCC using a combination of IgM-linked biomarkers**

A. Biasiolo, N. Tono, M. Briarava, L. Beneduce, G. Fassina, F. Farinati, A. Giacomini, C. Matteucci, R. Sorrentino, D. Nitti, A. Gatta, P. Pontisso - Padua, Venice, Rome

**N° 46 Erythropoietin administration seems to improve the decrease in platelet count observed during pegylated interferon and ribavirin treatment of patients with hepatitis C virus-related cirrhosis**

E.G. Giannini, M. Basso, S. Marengo, V. Fazio, G. Pieri, V. Savarino, A. Picciotto - Genoa

**N° 47 High prevalence of occult hepatitis C virus infection in non alcoholic steatohepatitis and cryptogenetic liver diseases**

C. Granieri, S. Bagaglio, E. Loggi, L. Porrino, C. Cursaro, L. Micco, E. Grandini, M. Bernardi, G. Morsica, P. Andreone - Bologna, Milan

**N° 48 Increasing ribavirin doses improves the sustained virological response in HCV patients not responding to pegylated interferon and ribavirin**

F. Conti, S. Lorenzini, A. Riili, C. Cursaro, A. Scuteri, E. Loggi, M. Bernardi, P. Andreone Bologna

**N° 49 Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking up a challenge for the hepatologist**

S. Lorenzini, L. Brodosi, A. Martello Panno, R. Di Donato, M. Biselli, S. Gitto, C. Cursaro, A. Scuteri, E. Loggi, L. Ridolfi, M. Cescon, A.D. Pinna, M. Bernardi, P. Andreone - Bologna

## Friday, February 25<sup>th</sup>

**N° 1 Identification of cancer stem cells in human hepatocellular and cholangiocellular carcinoma**

S. Lorenzini, E. Grandini, M. Masetti, E. Loggi, A. Martello Panno, L. Testa, E. Jovine, S.J. Forbes, M. Bernardi, P. Andreone - Bologna, Edinburgh (UK)

**N° 2 Pattern of drug-induced liver injury: the impact of amoxicillin-clavulanate on clinical course**

A. Licata, C. Randazzo, G. Butera, V. Calvaruso, A. Cali, M. Cappello, A. Craxi, P.L. Almasio Palermo

**N° 3 Characterization, back and follow-up of occult hepatitis B infection (OBI) among blood donors**

B. Foglieni, M. Spreafico, A. Berzuini, L. Raffaele, I. Guarnori, D. Prati - Lecco

**N° 4 Hemodynamic response to beta-blockers for portal hypertension: a single center experience**

C. Tiani, A. Berzigotti, L. Vizioli, V. Zorzi, D. Magalotti, M. Zoli - Bologna

**N° 5 Hepatocellular carcinoma (HCC) in cirrhosis: long-term results of percutaneous radiofrequency ablation of both the nodule and the portal venous tumor thrombus**

A. Giorgio, G. de Stefano, A. Di Sarno, N. Farella, U. Scognamiglio, A. De Rogatis, E. Trapanese, V. Giorgio - Naples

**N° 6 Efficacy and tolerability of peginterferon  $\alpha$ -2a and  $\alpha$ -2b in patients with chronic hepatitis C by genotype 1: a meta-analysis**

N. Coppola, M. Pisaturo, C. Sagnelli, G. Tonziello, E. Sagnelli, I.F. Angelillo - Naples

**N° 7 Insulin resistance does not affect sustained virologic response in patients with chronic hepatitis C without cirrhosis treated with peginterferon alfa 2a and ribavirin**

L. Chessa, G. Serra, C. Balestrieri, M. Conti, M. Casale, C. Calabrò, S. Cappellini, S. Casu, M. Iovine, E. Cossu, M.E. Lai, P. Farci - Cagliari

**N° 8 Hepatocellular carcinoma in cirrhosis extended in the main portal vein: a randomised controlled trial comparing percutaneous radiofrequency ablation of both hepatocellular carcinoma nodules and the portal venous tumor thrombus plus sorafenib with sorafenib alone**

A. Giorgio, N. Farella, A. Di Sarno, U. Scognamiglio, G. de Stefano, A. De Rogatis, E. Trapanese, V. Giorgio - Naples

**N° 9 Serum SCCA-IgM as a predictor of hepatocellular carcinoma (HCC) in patients with liver cirrhosis**

D. Buccione, G. Fatti, A. Gallotta, E. Loggi, R. Di Donato, L. Testa, C. Saitta, V. Santi, A. Di Micoli, V. Fazio, A. Picciotto, A. Biasiolo, P. Pontisso, G. Raimondo, F. Trevisani - Bologna, Messina, Genoa, Padua



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

**N° 10 Acute and chronic rejection during interferon therapy in HCV recurrent transplant patients: results from the AISF-RECOLT-C group**

M. Rendina, N.M. Castellaneta, S. Fagioli, F. Ponziani, R. Viganò, R.M. Iemmolo, M.F. Donato, P. Toniutto, L. Pasulo, M.C. Morelli, P. Burra, L. Miglioresi, V. Giannelli, D. Di Paolo, A. Di Leo on behalf of the AISF OLT Study group (RECOLT-C) - *Bari, Bergamo, Rome, Milan, Modena, Udine, Bologna, Padua*

**N° 11 Detection of HCV natural recombinant 2k/1b in Asian people living in Italy: a challenge for diagnostic tools**

R. Longo, M. Visca, S. Romano, M. Bernassola, G. Cappiello and A. Spano' - *Rome*

**N° 12 Isolation and evaluation of human hepatocytes for cell-based therapy**

R. Gramignoli, F. Marongiu, V. Tahan, K. Dorko, D. Geller, R. Venkataramanan, L. D'Antiga, E.C.S. Ellis and S.C. Strom - *Pittsburgh (PA, USA), Cagliari, Bergamo, Stockholm (Sweden)*

**N° 13 Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease**

A. Lisotti, F. Azzaroli, L. Turco, F. Buonfiglioli, P. Cecinato, C. Calvanese, F. Lodato, M. Montagnani, R. Golfieri, A. Colecchia, D. Festi, G. Mazzella - *Bologna*

**N° 14 Evidence of clonal evolution of tumor initiating cells in human hepatocellular carcinoma**

F. Colombo, L. Porretti, F. Balzan, S. Mazzucchelli, S. Guerner, M. Cadamuro, M. Spreafico, B. Foglieni, D. Prati - *Milan, Bergamo, Lecco*

**N° 15 Pre-S HBV mutants do not affect HBsAg serum levels in HBeAg negative genotype D carriers, but are associated with liver disease stage and older age**

A. Stabile, P. Colombatto, F. Oliveri, F. Moriconi, D. Cavallone, B. Cherubini, P. Ciccorossi, B. Coco, C. Rastelli, V. Romagnoli, F. Bonino and M.R. Brunetto - *Pisa*

**N° 16 Videocapsule endoscopy in portal hypertension: seek till you find**

I. Pentassuglio, M. Cesarini, L. Ridola, G. Fiorino, P. Vernia, O. Riggio - *Rome*

**N° 17 Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin resistance**

P. Dongiovanni, M. Ruscica, L. Benedan, V. Borroni, S. Recalcati, L. Steffani, L. Passafaro, G. Cairo, P. Magni, S. Gatti, S. Fargion, L. Valenti - *Milan*

**N° 18 Graft related gain in life expectancy according to MELD score in liver transplantation**

A. Vitale, R. Ramirez Morales, G. Zanusi, P. Burra, P. Angeli, U. Cillo - *Padua*

**N° 19 CD4+CD25hiFoxp3+ T-regs and liver transplantation for end-stage HCV-related liver disease: a role in HCV recurrence?**

S. Ferri, C. Lalanne, G. Lanzoni, M.C. Morelli, M. Bassi, P. Muratori, S. Berardi, M.R. Tamè, A. Gianstefani, M. Cescon, G. Ballardini, A.D. Pinna, M. Lenzi, L. Muratori - *Bologna, Rimini*

**N° 20 An increased and activated V $\delta$ 1 population characterises patients with active and advanced HCV-related liver disease**

S. Ferri, G. Lanzoni, C. Lalanne, M. Bassi, R. Cicola, A. Belardinelli, G. Ballardini, P. Muratori, G. Pappas, L. Muratori, M. Lenzi - *Bologna, Rimini*

**N° 21 Liver collagen proportionate area correlates with esophageal varices and SVR in patients with compensated HCV cirrhosis**

V. Calvaruso, V. Di Marco, D. Cabibbi, M.G. Bavetta, A. Craxi - *Palermo*

**N° 22 Spleen stiffness measurement as a non-invasive predictor of esophageal varices in cirrhotic patients**

A. Colecchia, L. Montrone, E. Scaiola, R. Schiumerini, L. Turco, G. Mazzella, D. Festi - *Bologna*

**N° 23 Liver related events and survival in patients with compensated HCV cirrhosis: the role of sustained virological response to PEG-IFN based therapy and portal hypertension**

V. Calvaruso, V. Di Marco, D. Ferraro, P. Pizzillo, G. Alaimo, A. Craxi - *Palermo*

**N° 24 Immune response and gender disparity influence liver regeneration after acute hepatic injury**

D. Arcidiacono, A. Cappon, D. Bizzaro, R. Di Liddo, C. Mescoli, T. Chioato, M.T. Conconi, P. Parnigotto, G.C. Sturniolo, M. Rugge, P. Burra, F.P. Russo - *Padua*



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- N° 25 Garlic extract reduces rat liver fibrosis and collagen content via TGF $\beta$  and tissue transglutaminase inactivation**  
F. Morisco, G. D'Argenio, G. Mazzone, M.T. Ribocco, P. Vitaglione, V. Lembo, M. Napolitano, V. Fogliano, N. Caporaso  
*Naples*
- N° 26 Changes in tumor stiffness for early prediction of tumor response to sorafenib: a proof-of-concept study with elastosonography in an animal model of hepatocellular carcinoma (HCC)**  
V. Salvatore, M. Baron Toaldo, S. Marinelli, C. Palamà, L. Gramantieri, M. Cipone, L. Bolondi, F. Piscaglia - *Bologna*
- N° 27 Hepatitis C virus modulates focal adhesion kinase promoting cytoskeletal reorganization in hepatocytes and a pro-fibrogenic phenotype in hepatic stellate cells**  
A. Alisi, M. Arciello, S. Pettrini, B. Conti, C. Balsano - *Rome, L'Aquila*
- N° 28 Systematic error in MELD calculation by using serum creatinine measurement in cirrhosis.**  
E. Tsochatzis, M. Garcovich, P. Manousou, G. Germani, G. Fede, E. Fatourou, D. Georgiadis, A.K. Burroughs, A. Gasbarrini  
*London (UK), Rome*
- N° 29 Reliability of serum creatinine in assessing renal function is reduced in patients with cirrhosis as compared with patients with organic renal disease**  
M. Garcovich, E. Tsochatzis, P. Manousou, G. Germani, G. Fede, E. Fatourou, D. Georgiadis, A.K. Burroughs, A. Gasbarrini  
*Rome, London (UK)*
- N° 30 IL28B genotype distribution and treatment outcome among patients with chronic hepatitis C (CHC): impact evaluation in a southern Europe population**  
S. Madonia, M.C. Renda, R. Ruggeri, G. Perricone, E. Sinagra, G. Malizia, S. Plano, F. Tinè, G. Giannuli, M. Olivo, A. Maggio, M. Cottone - *Palermo*
- N° 31 The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: results from the AISF-RECOLT-C group**  
M. Rendina, N.M. Castellaneta, S. Fagioli, F. Ponziani, R. Viganò, R.M. Iemmolo, M.F. Donato, P. Toniutto, L. Pasulo, M.C. Morelli, P. Burra, L. Miglioresi, V. Giannelli, D. Di Paolo, A. Di Leo on behalf of the AISF OLT Study group (RECOLT-C) - *Bari, Bergamo, Rome, Milan, Modena, Udine, Bologna, Padua*
- N° 32 Cytoplasmic rings/rods autoantibodies; a novel serum antibody developing during peginterferon therapy in patients with chronic hepatitis C**  
G. Covini, E. Bredi, W.C. Carcamo, G. Mangia, E. Grassi, M.G. Pich, E.K.L. Chan, M. Colombo  
*Rozzano, Gainesville (FL, USA), Milan*
- N° 33 High prevalence of reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides analogues treatment**  
M. Viganò, P. Lampertico, C. Eller-Vainicher, R. Soffredini, F. Facchetti, I. Chiodini, P. Beck-Peccoz, M. Colombo - *Milan*
- N° 34 Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience**  
P. Lampertico, M. Viganò, R. Soffredini, F. Facchetti, E. Minola, F. Suter, S. Zaltron, A. Vavassori, G. Gubertini, C. Magni, A. Testa, G. Antonucci, G. Pinzello, M. Vinci, E. Fatta, S. Fargion, P. Del Poggio, B. Coco, M.R. Brunetto, M. Andreoletti, T. Santantonio, G. Colloredo, S. Fagioli, A.E. Colombo, F. Fumagalli Maldini, M. Pozzi, N. Terreni, M. Quagliuolo, G. Lunghi, M. Colombo - *Milan, Bergamo, Brescia, Rome, Treviglio, Pisa, Lecco, Foggia, Como, Monza, Erba, Melegnano*
- N° 35 Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance**  
E. Vezali, P. Lampertico, F. Invernizzi, M. Iavarone, M. Viganò, F. Facchetti, G. Lunghi, M. Colombo - *Milan*
- N° 36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B**  
P. Lampertico, M. Viganò, C. Yurdaydin, R. Idilman, M. Buti, R. Esteban, G.V. Papatheodoridis, G. Pinzello, M. Vinci, E. Minola, F. Suter, P. Del Poggio, M. Andreoletti, S. Fagioli, A.E. Colombo, A. Salmi, T. Santantonio, C. Magni, G. Gubertini, F. Fumagalli Maldini, N. Terreni, F. Facchetti, R. Soffredini, M. Colombo - *Milan, Ankara (Turkey), Barcelona (Spain), Athens (Greece), Bergamo, Treviglio, Lecco, Como, Brescia, Foggia, Monza*
- N° 37 Management of extra hepatic portal vein obstruction in children**  
D. Alberti, M. Colusso, M. Cheli, P. Stroppa, R. Agazzi, A. Indriolo, L. D'Antiga - *Bergamo*



# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- N° 38 Contrast-enhanced ultrasound and serological biomarkers for early evaluation of clinical outcome of HCC sorafenib treatment**  
A. Olivani, C. Schianchi, E. Biasini, D. Laccabue, C. Mori, S. Giuliotti, S. Salvagni, F. Negri, A. Ardizzoni, G. Pelosi, C. Ferrari, G. Missale  
*Parma*
- N° 39 Is the primary immunosuppressive drug playing a role on the response to antiviral treatment for post-transplant HCV recurrence?**  
V. Vero, M. Senzolo, L. Pasulo, F.R. Ponziani, R. Viganò, M. Marino, M.F. Donato, M. Rendina, P. Toniutto, M. Cescon, E. De Martin, L. Miglioresi, V. Giannelli, D. Di Paolo, S. Fagioli on behalf of AISF RECOLT Study Group
- N° 40 Liver expression of IFN $\alpha$ / $\beta$  direct target genes and treatment outcomes in HCV infection**  
B. Testoni, S. Maimone, L. Covolo, C. Scisciani, F. Donato, T. Pollicino, V. Di Marco, M. Levrero and the Multicenter Italian Group for the Study of Hepatitis C - *Rome, Messina, Brescia, Palermo*
- N° 41 Chromatin dynamics of genes repression in response to IFN $\alpha$  reveal new roles for STAT2, phospho-STAT2, histone deacetylases (HDACs) and histone methylation marks**  
B. Testoni, C. Völlenkle, F. Guerrieri, S. Gerbal, G. Blandino and M. Levrero - *Rome, Villejuif (France), Montpellier (France)*
- N° 42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance**  
M. Levrero, L. Cimino, P. Lampertico, M. Viganò, G.B. Gaeta, G. Brancaccio, E. Sagnelli, V. Messina, G. Raimondo, A. Marzano, S. Fagioli, G. Niro, T. Santantonio, M. Puoti, V. Di Marco, G. Mazzella, G. Di Costanzo, M. Angelico, S. Pierconti, C. Sava', M. Subic for the OptiB Study Group - *Rome, Milan, Naples, Caserta, Messina, Turin, Bergamo, San Giovanni Rotondo, Bari, Brescia, Palermo, Bologna*
- N° 43 A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice**  
V. Di Marco, L. Covolo, M. Levrero, M. Puoti, F. Suter, G.B. Gaeta, C. Ferrari, G. Raimondo, G. Fattovich, T. Santantonio, A. Alberti, R. Bruno, C. Mussini, M. Mondelli, F. Donato, A. Craxì on behalf of the Multicenter Italian Group for the Study of Hepatitis C
- N° 44 Treatment and productivity costs of chronic hepatic diseases**  
L. Scalone, R. Ciampichini, S. Fagioli, I. Gardini, L. Gaeta, A. Del Prete, F. Fusco, L.G. Mantovani  
*Milan, Bergamo, Naples*
- N° 45 Early liver steatosis during choline-deficient diet is associated with altered distribution of caveolin-1 (CAV1) within lipid droplets and mitochondria in steatotic rat hepatocytes**  
M. Mastrodonato, G. Calamita, R. Rossi, D. Mentino, L. Bonfrate, P. Portincasa, D. Ferri, G.E. Liquori - *Bari*
- N° 46 HBx-specific immune response in hepatitis B patients with different stage of disease**  
L. Testa, E. Loggi, C. Cursaro, S. Lorenzini, C. Granieri, R. Di Donato, M. Bernardi, P. Andreone - *Bologna*
- N° 47 The adipokine chemerin as a novel factor regulating the fibrogenic phenotype of human hepatic stellate cells**  
S. Galastri, S. Madaï, A. Caligiuri, A. Provenzano, M. Pinzani, F. Marra - *Florence*
- N° 48 HCV relapses occur within 3 months after treatment in liver transplanted patients receiving pegylated IFN and ribavirin**  
U. Visco-Comandini, L. Miglioresi, R. Lionetti, M. Montalbano, L. Loiacono, G. Vennarecci, R. Santoro, G.M. Ettore - *Rome*
- N° 49 A randomized multicentre double-blind vs placebo trial: evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease**  
P. Andreone, M.C. Brisc, M. Chiamonte, A. Federico, A. Floreani, M.A. Freni, A. Grieco, S. Lobello, S. Milani, L. Okolicsanyi, P. Portincasa, A. Smedile, I. Sporea, P. Sorrentino, R. Vecchione, C. Tuccillo, C. Loguercio - *Paola (CZ), Oradea (Romania), Negrar (VR), Naples, Padua, Messina, Rome, Florence, Treviso, Bari, Turin, Timisoara (Romania)*





# AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

## **4<sup>th</sup> AISF POST-MEETING COURSE** **“Unmet Clinical Needs in Hepatology”** **“new and upcoming diagnostic tools”**

Auditorium, Centro Congressi Frentani - Via dei Frentani, 4  
Rome, February 26<sup>th</sup>, 2011

Course Directors: M. Fraquelli, Milan and G. Missale, Parma

### **Saturday, February 26<sup>th</sup>**

08.30-08.45 Registration of Participants

08.45-08.50 Course Presentation  
M. Fraquelli & G. Missale

#### Session I **DIAGNOSTIC PROCEDURES** Chairperson: C. Balsano, Rome

08.50-09.10 Molecular tools for the NUCs non-response in chronic HBV infection  
T. Pollicino, Messina

09.10-09.30 Genetic and virological approaches for the treatment of HCV positive patients  
E. Villa, Modena

09.30-09.50 Pathological diagnosis of dysplasia and early HCC  
M. Guido, Padua

09.50-10.10 Assessment of response after non surgical treatment of HCC  
L. Bolondi, Bologna

10.10-10.40 Discussion

10.40-11.10 Break

#### Session II **NON INVASIVE DIAGNOSTIC TOOLS FOR STAGING LIVER DISEASE**

Chairperson: M.R. Brunetto, Pisa

11.10-11.30 Methodological approach: Study design and predictive models  
A. Colli, Lecco

11.30-11.50 Serological markers  
F. Marra, Florence

11.50-12.10 Transient elastography in chronic viral liver diseases  
C. Rigamonti, Milan

12.10-12.30 Transient elastography in chronic liver diseases of other etiologies  
V. Calvaruso, Palermo

12.30-12.50 Novel technologies (ARFI, Magnetic resonance)  
F. Piscaglia, Bologna

12.50-13.20 Discussion

13.20 Closure of the Course